Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study

The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.

Results from Recursion Pharmaceuticals, Inc.’s Phase II SYCAMORE study of REC-994 in symptomatic cerebral cavernous malformation (CCM) drew uncertainty despite meeting the trial’s safety and tolerability primary endpoint, as the study showed signals of efficacy, but in a disease where there is a lack of clarity on what constitutes success.

Salt Lake City, UT-based Recursion announced the SYCAMORE results on 3 September, saying that the drug demonstrated “encouraging trends” in...